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ETATE-OF-THE-ART PAPER2701Prognostic Value of Biomarkers Related to Fibrinolysisiana A. Gorog
ypoactive endogenous fibrinolysis may increase the risk of thrombotic cardiovascular events.
his review by Gorog covers 45 studies in nearly 50,000 subjects that examined the
ssociation between plasma markers of fibrinolysis and future cardiovascular events. The
eported predictive value of plasma levels of tissue-type plasminogen activator, plasminogen
ctivator inhibitor-1, plasmin-antiplasmin complex, D-dimer, thrombin activatable fibrinolysis
nhibitor, and lipoprotein(a) is highly variable and conflicting. The physiological limitations of
uch markers in reflecting endogenous fibrinolysis is discussed. These results suggest that
ewly described global assays of fibrinolysis will require large-scale clinical trials before their
rognostic power or superiority to multiple biomarker measurements can be evaluated.CLINICAL RESEARCH LINICAL TRIALS2710Similar Efficacy of SES and PES for In-Stent Restenosis With SES0
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2 3ulinda Mehilli, Robert A. Byrne, Klaus Tiroch, Susanne Pinieck, Stefanie Schulz, Sebastian Kufner,
teffen Massberg, Karl-Ludwig Laugwitz, Albert Schömig, Adnan Kastrati, for the ISAR-DESIRE 2
nvestigators
hile in-stent restenosis (ISR) is less frequent with drug-eluting stents (DES), it still occurs.
t remains to be determined whether implantation of a DES eluting the same type of drug—
so-called “homo-DES” approach—is preferable to a switch to a DES eluting a different
lass of drug—a “hetero-DES” strategy. The ISAR-DESIRE 2 (Intracoronary Stenting and
ngiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) trial randomized
atients with a sirolimus-eluting stent (SES) who developed ISR to repeat stenting with
ither SES or a paclitaxel-eluting stent (PES). There was no difference in outcomes, with
imilar rates of in-stent late lumen loss, binary restenosis, target lesion revascularization, and
tent thrombosis. In cases of SES restenosis, similar safety and efficacy is seen with either
epeat SES or a switch to PES.
ditorial Comment: Fernando Alfonso, p. 2717(continued on page A-23)
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aLINICAL TRIALS2721Final Results From the ARBITER 6-HALTS Trialodd C. Villines, Eric J. Stanek, Patrick J. Devine, Mark Turco, Michael Miller, Neil J. Weissman,
en Griffen, Allen J. Taylor
he ARBITER 6-HALTS (Arterial Biology for the Investigation of the Treatment Effects
f Reducing Cholesterol 6–HDL and LDL Treatment Strategies in Atherosclerosis) trial,
hich randomized subjects who were already taking a statin to extended-release niacin or
zetimibe, was terminated early when an interim analysis showed superiority of niacin for the
rimary end point, which was change in carotid intima-media thickness (CIMT). Following
ermination of the study, an additional 107 subjects completed a close-out assessment; this
aper incorporates those assessments. Niacin resulted in significant reduction (regression) in
ean and maximal CIMT, whereas there were no significant changes with ezetimibe. Further
nalysis linked increased cumulative drug exposure to greater regression of CIMT with niacin,
ompared with progression with ezetimibe. Niacin induces regression of CIMT and is
uperior to ezetimibe for this end point in patients taking statins.LINICAL TRIALS
2727elipidated Plasma May Promote Reverse
Cholesterol Transport and Atheroma Regressionon Waksman, Rebecca Torguson, Kenneth M. Kent, Augusto D. Pichard, William O. Suddath,
owell F. Satler, Brenda D. Martin, Timothy J. Perlman, Jo-Ann B. Maltais, Neil J. Weissman,
eter J. Fitzgerald, H. Bryan Brewer, Jr
revious research suggests that a type of plasmapheresis designed to delipidate plasma
onverts spherical mature -high-density lipoprotein (HDL) to disc-shaped, nascent
re-like HDL, which is important for reverse cholesterol transport. This study aimed to
etermine the safety and feasibility of this technique, which uses autologous infusions of
elective HDL delipidated plasma. Twenty-eight patients who presented with an acute
oronary syndrome and had a nonculprit lesion suitable for serial intravascular ultrasound were
andomized to 7 weekly infusions of the active treatment or a sham protocol. All reinfusion
essions were tolerated well. The levels of pre-like HDL and HDL in the delipidated
lasma converted from 6% to 79% and 93% to 21%, respectively. The intravascular ultrasound
ata demonstrated a trend toward regression in total atheroma volume in the treatment
roup. Autologous infusions of selective HDL delipidated plasma may promote coronary
theroma regression, and larger studies appear warranted.(continued on page A-28)
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EIPIDS AND CORONARY RISK2736Clinical Predictors of Plaque Progression Despite LDL-C <70 mg/dlzgur Bayturan, Samir Kapadia, Stephen J. Nicholls, E. Murat Tuzcu, Mingyuan Shao, Kiyoko Uno,
jai Shreevatsa, Andrea J. Lavoie, Kathy Wolski, Paul Schoenhagen, Steven E. Nissen
ayturan and colleagues compiled data from several serial intravascular ultrasound studies to
etermine why approximately 20% of subjects had progression in the percent atheroma
olume despite achieving very low levels of low-density lipoprotein cholesterol (LDL-C).
rogression was defined as a 5% increase in percent atheroma volume (PAV). Independent
redictors of progression in patients with LDL-C 70 mg/dl included baseline PAV,
iabetes, increase in systolic blood pressure, less increase in high-density lipoprotein
holesterol, and a smaller decrease in apolipoprotein (apo)B levels, but not changes in
-reactive protein or LDL-C. Residual risk factors, particularly higher apoB levels, are
ssociated with atheroma progression.ditorial Comment: Basil S. Lewis, David A. Halon, p. 2743EART RHYTHM DISORDERS2745Genetic Polymorphisms May Modify Risk in Patients With LQTSarta Toma´s, Carlo Napolitano, Luciana De Giuli, Raffaella Bloise, Isaac Subirana, Alberto Malovini,
iccardo Bellazzi, Dan E. Arking, Eduardo Marban, Aravinda Chakravarti, Peter M. Spooner,
ilvia G. Priori
oma´s and colleagues investigated the role of polymorphisms in the NOS1AP gene as a
otential risk modifier for patients with long QT syndrome (LQTS). This study included
01 patients enrolled in a prospective LQTS registry. Three NOS1AP marker single
ucleotide polymorphisms were genotyped to assess their relationship to corrected QT (QTc)
nterval and cardiac events. Two of the 3 variant alleles were associated with small increases in
Tc interval and 2 were linked to a higher incidence of cardiac events. These results providehe first demonstration of a risk-conferring genetic modifier in a large LQTS cohort.EART RHYTHM DISORDERS
2753erum Markers of Collagen Turnover Predict Future Arrhythmias
in Patients With Nonischemic Cardiomyopathymmanuel M. Kanoupakis, Emmanuel G. Manios, Eleftherios M. Kallergis, Hercules E. Mavrakis,
hristos A. Goudis, Ilias G. Saloustros, Maria E. Milathianaki, Gregory I. Chlouverakis, Panos E. Vardas
anoupakis and colleagues hypothesized that alterations in the extracellular matrix (ECM)
ay contribute to electrical heterogeneity, and thereby the risk of ventricular arrhythmias, in
atients with nonischemic dilated cardiomyopathy (NIDC). Serum markers of collagen
urnover were measured in 70 patients with NIDC referred for an implantable cardioverter-
efibrillator (ICD). Pre-implantation serum concentrations of C-terminal telopeptide of
ollagen type-I, matrix metalloproteinase-1, and tissue inhibitor of matrix metalloproteinases-1
ere significantly higher in patients who had appropriate ICD-delivered therapy than in
hose who did not. Measuring serum markers of collagen turnover may help to identify
ubjects with NIDC who are likely to benefit from an ICD.ditorial Comment: Gregory M. Marcus, p. 2760
(continued on page A-32)
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mARDIAC IMAGING
2762uantitation of Infarct Core and Border Zone
With CMR Can Stratify Risk of Future CVEhahriar Heidary, Harendra Patel, Jaehoon Chung, Hajime Yokota, Sandeep N. Gupta,
ihoko V. Bennett, Chandra Katikireddy, Patricia Nguyen, John M. Pauly, Masahiro Terashima,
ichael V. McConnell, Phillip C. Yang
rior studies have demonstrated that quantification of myocardial scar volume by cardiac
agnetic resonance (CMR) is superior to ejection fraction for predicting future cardiovascular
vents (CVE) in patients with ischemic cardiomyopathy (ICM). Heidary and colleagues note
hat this scar can be heterogeneous with areas of high late gadolinium enhancement, which
orrelates with scar, and a border zone with levels of enhancement higher than normal
yocardium but lower than true scar. Seventy patients with ICM who underwent a CMR
ere followed. The 41% of patients who experienced a CVE had larger infarct border zones
hether measured in grams or percent of myocardium. On the other hand, the extent of core
nfarct, left ventricular end-diastolic volume, left ventricular end-systolic volume, and left
entricular ejection fraction were not associated with increased risk. Quantification of the core
nd border zones of infarcted myocardium may be useful for identifying high-risk patients.ARDIAC IMAGING2769123-I MIBG Imaging Predicts Ventricular Arrhythmias in ICD Patientsark J. Boogers, C. Jan Willem Borleffs, Maureen M. Henneman, Rutger J. van Bommel,
an van Ramshorst, Eric Boersma, Petra Dibbets-Schneider, Marcel P. Stokkel, Ernst E. van der Wall,
artin J. Schalij, Jeroen J. Bax
imited data are available on the predictive value of sympathetic nerve imaging with
23-iodine metaiodobenzylguanidine (123-I MIBG) for ventricular arrhythmias. Prior to
mplantable cardioverter-defibrillator (ICD) implantation, early and late 123-I MIBG (planar
nd single-photon emission computed tomography [SPECT]) imaging was performed (heart-
o-mediastinum ratio, cardiac washout rate, and 123-I MIBG SPECT defect score). Stress-
est myocardial perfusion imaging was also performed. The late 123-I MIBG SPECT defect
core was an independent predictor for arrhythmias requiring ICD therapy during 3 years of
ollow-up. Measuring cardiac sympathetic denervation with 123-I MIBG imaging may be
seful for assessing the risk of ventricular arrhythmias.EDIATRIC CARDIOLOGY2778Elevated Maternal Anti-Ro/SSA Antibodies Linked to Cardiac NLEdgar Jaeggi, Carl Laskin, Robert Hamilton, John Kingdom, Earl Silverman
aeggi and colleagues sought to determine if cardiac complications of neonatal lupus
rythematosus (NLE) can be predicted by measuring maternal anti-Ro and -La levels using a
ase-control format. Forty fetuses/neonates with a diagnosis of heart block, endocardial
broelastosis, or both were compared with 146 serially-screened healthy fetuses. All cardiac
omplications occurred when maternal anti-Ro levels were high. For instance, the rate of
omplete heart block was 5% in those with anti-Ro levels 50 U/ml. Infants with pre-natal
xposure to high anti-La levels were more likely to develop noncardiac features of NLE.
hese findings suggest that low maternal titers of anti-Ro need not trigger frequent serial
onitoring.
